Here are Monday's biggest analyst calls: Nvidia, Micron, Tesla, FedEx, BP, Dell, Starz, Wendy's, Affirm & more

Wall Street commentary was broadly positive, with multiple upgrades and new buy initiations across Micron, Tesla, BP, Primoris, StandardAero, Affirm, Nvidia, and others. Highlights include D.A. Davidson reiterating Micron at Buy with a $1,000 target, Piper Sandler remaining Overweight on Tesla, and Bank of America raising Affirm's target to $88 from $82 after a beat-and-raise quarter. Offsetting the positives, UBS downgraded Dell to Neutral and JPMorgan cut Wendy's to Underweight.

Analysis

The market is still rewarding scarcity plus duration: names tied to AI infrastructure, specialty aerospace, and data-center capex continue to get multiple expansion because investors are willing to underwrite multi-year earnings visibility over near-term cyclicality. That creates a second-order setup where the suppliers to the buildout, not just the headline beneficiaries, can keep rerating as backlog converts and pricing remains tight; MU, NVDA, PRIM, and STAE-like maintenance/aerospace names are the cleanest expression of that trade.

The clearest loser in the group is DELL: when a stock has already de-risked with a ~170% run, a neutral call can matter even without a fundamentals break. That matters because crowded AI hardware baskets are now more sensitive to any hint of margin normalization, and capital can rotate from integrators toward component suppliers and enablers with better operating leverage. A similar dynamic applies in logistics: FDX/CHRW can benefit if rate discipline holds into peak season, but any demand wobble would compress the upside quickly because these are still throughput stories, not secular compounders.

On the consumer side, WEN looks like a classic “longer than expected” turnaround casualty: leadership uncertainty plus traffic deterioration tends to keep valuation depressed until there is a hard catalyst, not just a better quarter. In contrast, AFRM still has the cleaner setup because the debate is shifting from funding-model skepticism to unit economics and conversion, but the stock remains highly sensitive to macro credit data over the next 1-2 quarters. The China hotel upgrades (ATAT/HTHT) are a reminder that international leisure exposure is being re-rated on normalized demand, but that trade only works if Chinese consumer confidence doesn’t roll over again.

The contrarian angle is that the strongest bullish calls are also the most consensus-adjacent: NVDA and MU likely have good prints already embedded, so upside comes from guide quality rather than headline beats. The more interesting mispricing is in underappreciated beneficiaries with explicit idiosyncratic drivers — StandardAero, Primoris, and Madison Air — where estimate revisions can compound for several quarters if the thematic demand persists. For biotech, BBOT is a high-beta catalyst stock; upside can be sharp, but without clinical/data follow-through it can give back gains just as fast.

Key Decisions for Investors

• Go long MU vs short DELL for 1-3 months: both trade in AI hardware, but MU has upside from a more favorable supply/demand setup while DELL is vulnerable to multiple compression after a huge run.
• Buy NVDA into the May 20 earnings window using call spreads, not stock: the setup favors a beat-and-raise, but implied expectations are elevated, so defined-risk upside is better than chasing delta.
• Add PRIM on weakness for a 3-6 month hold: renewable execution issues look transitory, and the stock offers better rerating potential than the headline power-utility complex if estimates stabilize.
• Long AFRM with a tight risk stop over the next 4-8 weeks: the near-term catalyst path is cleaner after a solid print, but the position must be sized for macro/funding volatility.
• Avoid or short WEN on any bounce: absent leadership clarity and same-store-sales inflection, the stock lacks a catalyst and can remain a value trap for several quarters.